Mizuho lowered the firm’s price target on Harmony Biosciences to $40 from $42 and keeps a Buy rating on the shares. The firm left the company’s Q4 results announced last week with its bullish thesis intact. The analyst adjusted the estimated launch timeline for ZYN002 in Fragile X syndrome to 2027 versus 2026 prior.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
- Harmony Biosciences Releases Investor Presentation Update
- Harmony Biosciences reports Q4 adjusted EPS 73c, consensus 48c
- Harmony Biosciences: FDA grants priority review for sNDA for WAKIX
- Harmony Biosciences’ pitolisant designated Orphan Drug in Prader-Willi syndrome
